Drugs / SP-624
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06570369 | Aug 2024 → May 2026 | major depressive disorder | Sirtsei Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04510298 | Oct 2020 → Apr 2021 | schizophrenia | Sirtsei Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT06254612 | Mar 2024 → Jul 2026 overdue | major depressive disorder | Sirtsei Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04479852 | Sep 2020 → Jun 2022 | major depressive disorder | Sirtsei Pharmaceuticals, Inc. | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SP-624 | “A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.” PMID 41099447 ↗ Oct 2025 |
| Known as | forvisirvat | “A phase 2, multicenter, double-blind, randomized, placebo-controlled study of the safety and efficacy of forvisirvat (SP-624) in the treatment of adults with major depressive disorder.” PMID 41099447 ↗ Oct 2025 |
| Action | Activate | “SIRT6) activator” PMID 41099447 ↗ Oct 2025 |
| Route | Oral | “Daily oral capsule, 20 mg/day” NCT04479852 ↗ |
| Target | SIRT6 | “sirtuin 6 (SIRT6) activator” PMID 41099447 ↗ Oct 2025 |